92 related articles for article (PubMed ID: 27117748)
1. Disruption of Epac1 protects the heart from adenylyl cyclase type 5-mediated cardiac dysfunction.
Cai W; Fujita T; Hidaka Y; Jin H; Suita K; Prajapati R; Liang C; Umemura M; Yokoyama U; Sato M; Okumura S; Ishikawa Y
Biochem Biophys Res Commun; 2016 Jun; 475(1):1-7. PubMed ID: 27117748
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart.
Zhao Z; Babu GJ; Wen H; Fefelova N; Gordan R; Sui X; Yan L; Vatner DE; Vatner SF; Xie LH
Am J Physiol Heart Circ Physiol; 2015 Feb; 308(3):H240-9. PubMed ID: 25485900
[TBL] [Abstract][Full Text] [Related]
3. Cardiac overexpression of Epac1 in transgenic mice rescues lipopolysaccharide-induced cardiac dysfunction and inhibits Jak-STAT pathway.
Jin H; Fujita T; Jin M; Kurotani R; Namekata I; Hamaguchi S; Hidaka Y; Cai W; Suita K; Ohnuki Y; Mototani Y; Shiozawa K; Prajapati R; Liang C; Umemura M; Yokoyama U; Sato M; Tanaka H; Okumura S; Ishikawa Y
J Mol Cell Cardiol; 2017 Jul; 108():170-180. PubMed ID: 28629760
[TBL] [Abstract][Full Text] [Related]
4. Exchange-protein activated by cAMP (EPAC) regulates L-type calcium channel in atrial fibrillation of heart failure model.
Zhang MX; Zheng JK; Wang WW; Kong FQ; Wu XX; Jiang JK; Pan JX
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2200-2207. PubMed ID: 30915767
[TBL] [Abstract][Full Text] [Related]
5. Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling.
Surinkaew S; Aflaki M; Takawale A; Chen Y; Qi XY; Gillis MA; Shi YF; Tardif JC; Chattipakorn N; Nattel S
Cardiovasc Res; 2019 Jan; 115(1):94-106. PubMed ID: 30016400
[TBL] [Abstract][Full Text] [Related]
6. The type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA/STAT3-dependent pathway.
Wu YS; Chen CC; Chien CL; Lai HL; Jiang ST; Chen YC; Lai LP; Hsiao WF; Chen WP; Chern Y
J Biomed Sci; 2017 Sep; 24(1):68. PubMed ID: 28870220
[TBL] [Abstract][Full Text] [Related]
7. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress.
Okumura S; Vatner DE; Kurotani R; Bai Y; Gao S; Yuan Z; Iwatsubo K; Ulucan C; Kawabe J; Ghosh K; Vatner SF; Ishikawa Y
Circulation; 2007 Oct; 116(16):1776-83. PubMed ID: 17893275
[TBL] [Abstract][Full Text] [Related]
8. Annexin A4 is a novel direct regulator of adenylyl cyclase type 5.
Heinick A; Husser X; Himmler K; Kirchhefer U; Nunes F; Schulte JS; Seidl MD; Rolfes C; Dedman JR; Kaetzel MA; Gerke V; Schmitz W; Müller FU
FASEB J; 2015 Sep; 29(9):3773-87. PubMed ID: 26023182
[TBL] [Abstract][Full Text] [Related]
9. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses.
Okumura S; Fujita T; Cai W; Jin M; Namekata I; Mototani Y; Jin H; Ohnuki Y; Tsuneoka Y; Kurotani R; Suita K; Kawakami Y; Hamaguchi S; Abe T; Kiyonari H; Tsunematsu T; Bai Y; Suzuki S; Hidaka Y; Umemura M; Ichikawa Y; Yokoyama U; Sato M; Ishikawa F; Izumi-Nakaseko H; Adachi-Akahane S; Tanaka H; Ishikawa Y
J Clin Invest; 2014 Jun; 124(6):2785-801. PubMed ID: 24892712
[TBL] [Abstract][Full Text] [Related]
10. Developmental changes in gene expression of Epac and its upregulation in myocardial hypertrophy.
Ulucan C; Wang X; Baljinnyam E; Bai Y; Okumura S; Sato M; Minamisawa S; Hirotani S; Ishikawa Y
Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1662-72. PubMed ID: 17557924
[TBL] [Abstract][Full Text] [Related]
11. Coupling of β1-adrenergic receptor to type 5 adenylyl cyclase and its physiological relevance in cardiac myocytes.
Tsunematsu T; Okumura S; Mototani Y; Ohnuki Y; Jin H; Cai W; Suita K; Sato I; Umemura M; Yokoyama U; Sato M; Fujita T; Ishikawa Y
Biochem Biophys Res Commun; 2015 Mar; 458(3):531-535. PubMed ID: 25677623
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Exchanged Protein Directly Activated by cAMP (Epac)1-Inhibiting Therapy for Prevention of Atrial and Ventricular Arrhythmias in Mice.
Prajapati R; Fujita T; Suita K; Nakamura T; Cai W; Hidaka Y; Umemura M; Yokoyama U; Knollmann BC; Okumura S; Ishikawa Y
Circ J; 2019 Jan; 83(2):295-303. PubMed ID: 30518738
[TBL] [Abstract][Full Text] [Related]
13. Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2-adrenoceptor stimulation.
Ohnuki Y; Umeki D; Mototani Y; Jin H; Cai W; Shiozawa K; Suita K; Saeki Y; Fujita T; Ishikawa Y; Okumura S
J Physiol; 2014 Dec; 592(24):5461-75. PubMed ID: 25344550
[TBL] [Abstract][Full Text] [Related]
14. Disruption of type 5 adenylyl cyclase prevents β-adrenergic receptor cardiomyopathy: a novel approach to β-adrenergic receptor blockade.
Yan L; Vatner SF; Vatner DE
Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1521-8. PubMed ID: 25193472
[TBL] [Abstract][Full Text] [Related]
15. The role of Epac in the heart.
Fujita T; Umemura M; Yokoyama U; Okumura S; Ishikawa Y
Cell Mol Life Sci; 2017 Feb; 74(4):591-606. PubMed ID: 27549789
[TBL] [Abstract][Full Text] [Related]
16. Cyclic AMP-binding protein Epac1 acts as a metabolic sensor to promote cardiomyocyte lipotoxicity.
Laudette M; Sainte-Marie Y; Cousin G; Bergonnier D; Belhabib I; Brun S; Formoso K; Laib L; Tortosa F; Bergoglio C; Marcheix B; Borén J; Lairez O; Fauconnier J; Lucas A; Mialet-Perez J; Moro C; Lezoualc'h F
Cell Death Dis; 2021 Sep; 12(9):824. PubMed ID: 34471096
[TBL] [Abstract][Full Text] [Related]
17. Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase.
Iwatsubo K; Bravo C; Uechi M; Baljinnyam E; Nakamura T; Umemura M; Lai L; Gao S; Yan L; Zhao X; Park M; Qiu H; Okumura S; Iwatsubo M; Vatner DE; Vatner SF; Ishikawa Y
Am J Physiol Heart Circ Physiol; 2012 Jun; 302(12):H2622-8. PubMed ID: 22505646
[TBL] [Abstract][Full Text] [Related]
18. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene.
Okumura S; Suzuki S; Ishikawa Y
J Pharmacol Sci; 2009 Mar; 109(3):354-9. PubMed ID: 19270422
[TBL] [Abstract][Full Text] [Related]
19. Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging.
Vatner SF; Park M; Yan L; Lee GJ; Lai L; Iwatsubo K; Ishikawa Y; Pessin J; Vatner DE
Am J Physiol Heart Circ Physiol; 2013 Jul; 305(1):H1-8. PubMed ID: 23624627
[TBL] [Abstract][Full Text] [Related]
20. Type 5 adenylyl cyclase disruption leads to enhanced exercise performance.
Vatner DE; Yan L; Lai L; Yuan C; Mouchiroud L; Pachon RE; Zhang J; Dillinger JG; Houtkooper RH; Auwerx J; Vatner SF
Aging Cell; 2015 Dec; 14(6):1075-84. PubMed ID: 26424149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
